Brokers Issue Forecasts for BrainsWay Ltd.’s FY2024 Earnings (NASDAQ:BWAY)

BrainsWay Ltd. (NASDAQ:BWAY) – Analysts at Northland Capmk increased their FY2024 earnings per share (EPS) estimates for BrainsWay in a report released on Thursday, October 3rd. Northland Capmk analyst C. Byrnes now forecasts that the company will earn $0.05 per share for the year, up from their prior forecast of $0.04. The consensus estimate for BrainsWay’s current full-year earnings is $0.06 per share. Northland Capmk also issued estimates for BrainsWay’s Q4 2024 earnings at $0.01 EPS, Q1 2025 earnings at $0.01 EPS, Q2 2025 earnings at $0.02 EPS, Q3 2025 earnings at $0.02 EPS, Q4 2025 earnings at $0.02 EPS and FY2025 earnings at $0.07 EPS.

BrainsWay (NASDAQ:BWAY) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $0.04 earnings per share for the quarter. BrainsWay had a return on equity of 1.45% and a net margin of 1.67%. The firm had revenue of $10.01 million for the quarter, compared to analyst estimates of $9.40 million. During the same quarter in the prior year, the company posted ($0.05) earnings per share.

A number of other research analysts have also weighed in on BWAY. Northland Securities upped their price objective on BrainsWay from $11.00 to $12.50 and gave the stock an “outperform” rating in a report on Thursday. HC Wainwright reiterated a “buy” rating and set a $16.00 target price on shares of BrainsWay in a research report on Monday, September 16th.

BrainsWay Price Performance

Shares of BWAY stock opened at $9.50 on Friday. The business’s fifty day moving average price is $7.83 and its 200 day moving average price is $6.54. BrainsWay has a 1-year low of $3.09 and a 1-year high of $9.72. The firm has a market capitalization of $158.32 million, a PE ratio of -105.56 and a beta of 1.26.

Institutional Investors Weigh In On BrainsWay

A number of large investors have recently bought and sold shares of BWAY. Acadian Asset Management LLC grew its holdings in shares of BrainsWay by 583.2% during the first quarter. Acadian Asset Management LLC now owns 175,416 shares of the company’s stock worth $923,000 after buying an additional 149,740 shares in the last quarter. Quadrature Capital Ltd purchased a new position in shares of BrainsWay during the fourth quarter valued at approximately $70,000. Perritt Capital Management Inc acquired a new stake in BrainsWay during the second quarter worth approximately $121,000. Rhumbline Advisers grew its stake in BrainsWay by 10.3% in the 2nd quarter. Rhumbline Advisers now owns 18,077 shares of the company’s stock worth $110,000 after acquiring an additional 1,695 shares during the period. Finally, Virtu Financial LLC acquired a new position in BrainsWay in the 1st quarter valued at $60,000. Institutional investors and hedge funds own 30.11% of the company’s stock.

About BrainsWay

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.